JPMorgan Chase & Co. Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $17.00
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $18.00 to $17.00 ...
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor ...
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
BioSpace8d
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...
Muscular Dystrophy News21h
MDA 2025: DYNE-101 improves finger function in DM1 clinical trial
Use of DYNE-101 is leading to improvements in muscle, and specifically finger, function in myotonic dystrophy type 1 patients ...
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...
Clinical Trials Arena on MSN8d
Dyne’s DMD trial advances patient mobility and dystrophin expression
The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...
Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251
Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...
Dyne wins new Outperform at BMO on prospects for lead drug
Dyne Therapeutics (NASDAQ:DYN) traded higher in the premarket on Wednesday after BMO Capital Markets launched its coverage with an Outperform recommendation and a $50 per share target, citing the ...
Dyne Therapeutics Names Editas Medicine's Lucera as CFO
Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at ...
Nasdaq4d
Dyne Therapeutics Appoints Erick J. Lucera as Chief Financial Officer to Support Late-Stage Clinical Programs
Dyne Therapeutics, Inc. announced the appointment of Erick J. Lucera as its new Chief Financial Officer, effective March 31, 2025. Lucera brings over 30 years of experience in the life sciences ...